Quantcast

Latest Eisai Inc. Stories

2014-06-13 12:23:30

Pre-Game Activities Honor Local Epilepsy Awareness Ambassador Families NEW YORK, June 13, 2014 /PRNewswire-iReach/ -- The Epilepsy Foundation of Metropolitan New York will host its 2(nd) Annual Epilepsy Awareness Day at Citi Field during a matchup between the New York Mets and the San Diego Padres at Citi Field on Father's Day, Sunday, June 15, 2014. The event will feature several exhibits and family activities designed to help raise public awareness about epilepsy and to celebrate...

2014-06-13 08:22:40

Pre-Game Activities Honor Local Epilepsy Awareness Ambassadors WOODCLIFF LAKE, N.J., June 13, 2014 /PRNewswire/ -- Eisai Inc. announced today it has become a "Keeper of the Flame" sponsor of the Epilepsy Foundation of Metropolitan New York's 2(nd) Annual Epilepsy Awareness Day which will take place during a baseball game between the New York Mets and the San Diego Padres at Citi Field on Father's Day, June 15, 2014. The event will feature several exhibits and family activities...

2014-06-09 08:28:41

WOODCLIFF LAKE, N.J. and SAN DIEGO, Calif., June 9, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ(®) (lorcaserin HCl) CIV will be presented at the American Diabetes Association's (ADA) 74th Scientific Sessions taking place June 13-17, 2014 in San Francisco, California. http://photos.prnewswire.com/prnvar/20120413/MM87168LOGO "Eisai is committed to advancing knowledge about the...

2014-05-31 08:20:45

Phase III data for lenvatinib to be presented at ASCO WOODCLIFF LAKE, N.J., May 31, 2014 /PRNewswire/ -- Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC). Progression-free survival with lenvatinib was extended significantly compared to placebo (HR=0.21, [99% CI: 0.14-0.31]; p<0.0001). The median...

2014-05-28 16:26:44

-- Pediatric Patients Aged 1 Month to Less Than 17 Years Now Have A New Option to Help Prevent Acute Chemotherapy-Induced Nausea and Vomiting -- WOODCLIFF LAKE, N.J. and LUGANO, Switzerland, May 28, 2014 /PRNewswire/ -- Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of ALOXI(®) (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly...

2014-05-15 08:29:02

Obesity Education Network Provides Tools to Help Physicians Assess and Manage Patients Who are Overweight or Obese WOODCLIFF LAKE, N.J., May 15, 2014 /PRNewswire/ -- Eisai Inc. today announced the launch of a website that will provide physicians with access to comprehensive clinical information that addresses obesity screening and risk assessment, provider-patient partnerships and weight loss management. The website, called the Obesity Education Network (OEN), www.obesityeducationnetwork.com,...

2014-05-14 20:23:42

Data underscore breadth of oncology portfolio WOODCLIFF LAKE, N.J., May 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that 10 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 30 to June 3, 2014. "Anchored by our human health care mission, Eisai's commitment to cancer patients and their families is evidenced by our focus on sometimes overlooked patient...

2014-05-09 08:26:05

-- Expansion to Approximately 600 Sales Specialists Follows Initiation of National Television Advertising Campaign -- SAN DIEGO, May 9, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai plans to add more than 200 new contract sales representatives to its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600, triple the size from the commercial launch of BELVIQ in June 2013. Eisai expects this expansion of the sales...

2014-05-09 08:25:56

Expansion Enables Eisai to Reach 90,000 Healthcare Providers WOODCLIFF LAKE, N.J., May 9, 2014 /PRNewswire/ -- Eisai Inc. announced today it will add more than 200 new contract sales representatives to its Metabolic Business Unit, bringing the total sales force for BELVIQ(®) to approximately 600, triple the size from when the FDA-approved prescription therapy for chronic weight management became available in June 2013. This expansion, which becomes effective on July 1, 2014, will allow Eisai...

2014-04-29 08:34:54

-- Doctors Can Help Patients Set Personal Weight Loss Goals: It's Not a One Size Fits All Approach -- WOODCLIFF LAKE, N.J., April 29, 2014 /PRNewswire/ -- Eisai Inc. today announced the launch of My Healthy(TM), an interactive and motivational campaign that shifts the focus of the obesity conversation away from just pounds lost to health gained. Almost 70 percent of Americans are affected by obesity or overweight. This movement emphasizes that those affected by obesity or overweight...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related